Down-regulated progesterone receptor A and B coinciding with successful treatment of endometrial hyperplasia by the levonorgestrel impregnated intrauterine system

References

• Horn LC, Schnurrbusch U, Bilek K, Hentschel B, Einenkel J. Risk of progression in complex and atypical endometrial hyperplasia: clinicopathologic analysis in cases with and without progestogen treatment. Int J Gynecol Cancer. 2004;14:348–53.
   PubMed Web of Science ®Google Scholar
• Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer. 1985;56:403–12.
   PubMed Web of Science ®Google Scholar
• Ferenczy A, Gelfand M. The biologic significance of cytologic atypia in progestogen-treated endometrial hyperplasia. Am J Obstet Gynecol. 1989;160:126–31.
   PubMed Web of Science ®Google Scholar
• Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under age 40. Obstet Gynecol. 1997;90:434–40.
   PubMed Web of Science ®Google Scholar
• Lindahl B, Alm P, Ferno M, Norgren A. Endometrial hyperplasia: a prospective randomized study of histopathology, tissue steroid receptors and plasma steroids after abrasio, with or without high dose gestagen treatment. Anticancer Res. 1990;10:725–30.
   PubMed Web of Science ®Google Scholar
• Vereide AB, Arnes M, Straume B, Maltau JM, Orbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2003;91:526–33.
   PubMed Web of Science ®Google Scholar
• Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev. 1990;11:266–301.
   PubMed Web of Science ®Google Scholar
• Vereide AB, Kaino T, Sager G, Arnes M, Orbo A. Effect of levonorgestrel IUD and oral medroxyprogesterone acetate on glandular and stromal progesterone receptors (PRA and PRB), and estrogen receptors (ER-alpha and ER-beta) in human endometrial hyperplasia. Gynecol Oncol. 2006;101:214–23.
   PubMed Web of Science ®Google Scholar
• Vereide AB, Kaino T, Sager G, Orbo A. Bcl-2, BAX, and apoptosis in endometrial hyperplasia after high dose gestagen therapy: a comparison of responses in patients treated with intrauterine levonorgestrel and systemic medroxyprogesterone. Gynecol Oncol. 2005;97:740–50.
   PubMed Web of Science ®Google Scholar
• Baak JP, Nauta JJ, Wisse-Brekelmans EC, Bezemer PD. Architectural and nuclear morphometrical features together are more important prognosticators in endometrial hyperplasias than nuclear morphometrical features alone. J Pathol. 1988;154:335–41.
   PubMed Web of Science ®Google Scholar
• Orbo A, Baak JP, Kleivan I, Lysne S, Prytz PS, Broeckaert MA, Computerised morphometrical analysis in endometrial hyperplasia for the prediction of cancer development. A long-term retrospective study from northern Norway. J Clin Pathol. 2000;53:697–703.
   PubMed Web of Science ®Google Scholar
• Baak JP, Mutter GL, Robboy S, van Diest PJ, Uyterlinde AM, Orbo A, The molecular genetics and morphometry-based endometrial intraepithelial neoplasia classification system predicts disease progression in endometrial hyperplasia more accurately than the 1994 World Health Organization classification system. Cancer. 2005;103:2304–12.
   PubMed Web of Science ®Google Scholar
• Orbo A, Arnes M, Hancke C, Vereide AB, Pettersen I, Larsen K. Treatment results of endometrial hyperplasia after prospective D-score classification A follow-up study comparing effect of LNG-IUD and oral progestins versus observation only. Gynecol Oncol. 2008;111:68–73.
   PubMed Web of Science ®Google Scholar
• Orbo A, Baak JP. Computer-based morphometric image analysis of endometrial hyperplasia. Tidsskr Nor Laegeforen. 2000;120:496–9.
   PubMedGoogle Scholar
• Huang A, Pettigrew NM, Watson PH. Immunohistochemical assay for oestrogen receptors in paraffin wax sections of breast carcinoma using a new monoclonal antibody. J Pathol. 1996;180:223–7.
   PubMed Web of Science ®Google Scholar
• Scarselli G, Tantini C, Colafranceschi M, Taddei GL, Bargelli G, Venturini N, Levo-norgestrel-nova-T and precancerous lesions of the endometrium. Eur J Gynaecol Oncol. 1988;9:284–6.
   PubMedGoogle Scholar
• Nilsson CG, Haukkamaa M, Vierola H, Luukkainen T. Tissue concentrations of levonorgestrel in women using a levonorgestrel-releasing IUD. Clin Endocrinol (Oxf). 1982;17:529–36.
   PubMed Web of Science ®Google Scholar
• Varma R, Soneja H, Bhatia K, Ganesan R, Rollason T, Clark TJ, The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia-A long-term follow-up study. Eur J Obstet Gynecol Reprod Biol. 2008;139:169–75.
   Google Scholar
• Perino A, Quartararo P, Catinella E, Genova G, Cittadini E. Treatment of endometrial hyperplasia with levonorgestrel releasing intrauterine devices. Acta Eur Fertil. 1987;18:137–40.
   PubMedGoogle Scholar
• Thomas P, Tubbs C, Garry VF. Progestin functions in vertebrate gametes mediated by membrane progestin receptors (mPRs): identification of mPRalpha on human sperm and its association with sperm motility. Steroids. 2009;74:614–21.
   Google Scholar
• Gellersen B, Fernandes MS, Brosens JJ. Non-genomic progesterone actions in female reproduction. Hum Reprod Update. 2009;15:119–38.
   PubMed Web of Science ®Google Scholar
• Nutu M, Weijdegard B, Thomas P, Bergh C, Thurin-Kjellberg A, Pang Y, Membrane progesterone receptor gamma: tissue distribution and expression in ciliated cells in the fallopian tube. Mol Reprod Dev. 2007;74:843–50.
   PubMed Web of Science ®Google Scholar
• Moe BT, Vereide AB, Orbo A, Jaeger R, Sager G. Levonorgestrel, medroxyprogesterone and progesterone cause a concentration-dependent reduction in endometrial cancer (Ishikawa) cell density, and high concentrations of progesterone and mifepristone act in synergy. Anticancer Res. 2009;29:1047–52.
   Google Scholar
• Orbo A, Moe BT, Gronaas H, Paulssen RH. Early effects of high concentrations of progesterone and mifepristone A gene expression study of endometrial cancer cells (Ishikawa). J Steroid Biochem Mol Biol. 2009;113:139–49.
   PubMed Web of Science ®Google Scholar
• Kampa M, Castanas E. Membrane steroid receptor signaling in normal and neoplastic cells. Mol Cell Endocrinol. 2006;246:76–82.
   Google Scholar
• Amezcua CA, Zheng W, Muderspach LI, Felix JC. Down-regulation of bcl-2 is a potential marker of the efficacy of progestin therapy in the treatment of endometrial hyperplasia. Gynecol Oncol. 1999;73:126–36.
   Google Scholar
• Maruo T, Laoag-Fernandez JB, Pakarinen P, Murakoshi H, Spitz IM, Johansson E. Effects of the levonorgestrel-releasing intrauterine system on proliferation and apoptosis in the endometrium. Hum Reprod. 2001;16:2103–8.
   PubMed Web of Science ®Google Scholar
• Oltvai ZN, Milliman CL, Korsmeyer SJ. Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 1993;74:609–19.
   PubMed Web of Science ®Google Scholar
• Wang H, Critchley HO, Kelly RW, Shen D, Baird DT. Progesterone receptor subtype B is differentially regulated in human endometrial stroma. Mol Hum Reprod. 1998;4:407–12.
   PubMed Web of Science ®Google Scholar
• Wang S, Pudney J, Song J, Mor G, Schwartz PE, Zheng W. Mechanisms involved in the evolution of progestin resistance in human endometrial hyperplasia – precursor of endometrial cancer. Gynecol Oncol. 2003;88:108–17.
   PubMed Web of Science ®Google Scholar